Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase I, first-in-human study
Gerd Rüdiger Burmester, Eugen Feist, Matthew A. Sleeman, Bing Wang, Barbara White, Fabio Magrini
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase I, first-in-human study'. Together they form a unique fingerprint.